Time to sell exosome therapies to patients? No. Some stem cell clinics and related firms are looking for new ways to make profits and toward that goal a few have latched onto the legitimate buzz around exosome research. What are exosomes? Imagine if you could bubble up a pea-sized sphere off your skin full of […]
As exosome work advances, clinics pitch unproven therapies to patients Read More »
Our California stem cell agency, CIRM, started as a baby even before I came to California in 2006 to start my lab here at UC Davis School of Medicine, but now CIRM or to use its full name the California Institute for Regenerative Medicine is I’d say a full-grown, mature adult at about age 13
Poll on refunding CIRM on eve of informational legislative hearing Read More »
When you get an FDA warning letter (like if you are a non-compliant stem cell clinic) you generally aren’t feeling too well after reading it, but now there’s an extra thing to worry about according to the FDA. A fake FDA warning letter. Apparently 3-dozen or more of these fake FDA warning letters sparked complains
Fake FDA warning letter scam Read More »
It’s an odd confluence of events this week that (A) the Nuffield Council, an ethics think tank, gives a thumbs up in a new report to heritable human genetic modification that would probably include using CRISPR in the same week that (B) a new paper reports that CRISPR can cause unpredictable genomic damage and several other concerning reports
Mixed Nuffield Council Report Too Aspirational on Human Genetic Modification Read More »
If it seems to you like dramatic cautionary tales about CRISPR accompanied by all sorts of media are coming at us more frequently, it’s not your imagination. In the latest yesterday, it was reported in a new paper led by Allan Bradley that CRISPR-Cas9 results in sometimes large-scale chromosomal lesions at or even away from the
Mulling over latest CRISPR tumult, this one from Nat Biot pub on DNA lesions Read More »
One of the reasons I’m a scientist is that I find biology fascinating and admittedly novel biomedical science can really catch my eye, but more recently as a somewhat grizzled researcher, I’ve become increasingly skeptical about some “sexy” research and media coverage of it. A small red flag went up for me as I was
Perspectives on uncritical NYT coverage of cardiac mitochondrial transplant trial Read More »
“If I’m going to the trouble of cloning myself, I want the clone to be a copy of me!” I’m imagining what someone might say if they were told that their expensive and ethically dubious personal cloning efforts produced a clone that was somebody else instead of them. Even if the clone was very similar
Surprising reason why human cloning may produce someone else Read More »
One of the highlights of Day 1 of #ISSCR2018 for me so far was the talk by Lorenz Studer (Co-Founder of BlueRock) on the use of human embryonic stem cell (HESC)-derived dopamine neurons for Parkinson’s Disease. Note that for this post and if I have time any others on this meeting, they are probably going
Lorenz Studer on Day 1 #ISSCR2018: HESC-based therapies for Parkinson’s Disease Read More »
Could potential associated cancer risks claw into CRISPR’s potential? The short answer from both previous and new data is that while CRISPR gene editing impacts the P53 pathway, which is involved in cancer along with having many other functions, this news is neither too surprising nor a fatal flaw, but some caution is warranted. CRISPR
Could Cancer Risk Claw CRISPR’s Potential? Some Balanced Perspectives Read More »
One of the most famous living biological scientists, Sir Ian Wilmut, just announced that he has Parkinson’s Disease. I wish him the best in dealing with this illness. Wilmut is very well-known for having cloned the first mammal, Dolly the Sheep. This work followed on the earlier breakthrough by Sir John Gurdon of cloning the
Ian Wilmut, who cloned Dolly, opens up about his Parkinson’s Disease Read More »